Abstract |
Patients with gastric or esophagogastric cancer treated with combination chemotherapy and rilotumumab, an anti-HGF monoclonal antibody, had longer progression-free survival than patients treated with chemotherapy alone, according to results from a phase II clinical trial. The survival benefit was greatest in patients with MET-positive disease; a phase III trial testing the drug combination's effect on this patient population is now under way.
|
Authors | |
Journal | Cancer discovery
(Cancer Discov)
Vol. 4
Issue 9
Pg. OF1
(Sep 2014)
ISSN: 2159-8290 [Electronic] United States |
PMID | 25185191
(Publication Type: Journal Article, Comment)
|
Copyright | ©2014 American Association for Cancer Research. |
Chemical References |
|
Topics |
- Adenocarcinoma
(drug therapy)
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Esophagogastric Junction
(pathology)
- Female
- Humans
- Male
- Stomach Neoplasms
(drug therapy)
|